The Japanese Data Center for Hematopoietic Cell Transplantation
- Research works
- 103 ▲ 159% vs 2013–17
- Citations
- 1.8k 17.2 per fractional work
- Top-10% rate
- 10.6% record average 16.5%
- Open access
- 43% world 28%
Not ranked overall: The Japanese Data Center for Hematopoietic Cell Transplantation is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 14.5×. Every wedge is a field page.
- Immunology and Microbiology 14.5×
- Medicine 3.9×
- Pharmacology, Toxicology and Pharmaceutics 1.0×
- Biochemistry, Genetics and Molecular Biology 0.9×
- Nursing 0.5×
- Agricultural and Biological Sciences 0.5×
- Economics, Econometrics and Finance 0.4×
- Health Professions 0.1×
- Business, Management and Accounting 0.1×
- Mathematics 0.1×
- Social Sciences 0.1×
- Computer Science 0.0×
- Neuroscience 0.0×
- Decision Sciences 0.0×
- Engineering 0.0×
Who are the top researchers at The Japanese Data Center for Hematopoietic Cell Transplantation?
Ranked on the composite score, Yoshiko Atsuta, Takahiro Fukuda and Takahiro Fukuda lead among researchers whose main affiliation is The Japanese Data Center for Hematopoietic Cell Transplantation.
- 1 Yoshiko Atsuta Japan · #427,330 worldwide 234 citations · 116 works
- 2 Takahiro Fukuda Japan · #647,874 worldwide 81 citations · 25 works
- 3 Takahiro Fukuda Japan · #853,582 worldwide 121 citations · 109 works
- 4 Yukiyasu Ozawa Japan · #915,601 worldwide 28 citations · 34 works
- 5 Ayumu Ito Japan · #1,545,118 worldwide 7 citations · 16 works
Which keywords describe research at The Japanese Data Center for Hematopoietic Cell Transplantation?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Hematopoietic Stem Cells, Mesenchymal Stem Cells, Bone Marrow Niche, Graft-versus-Host Disease, Prognostic Factors, Lymphoma, Acute Myeloid Leukemia and AML.
- Transplant Recipients
- CD4+CD25+
- Autoimmunity
- TGF-ß
- NK Cell Recognition
- Imatinib
- Inflammation
- Chimeric Antigen Receptor
- Rituximab
- Cancer Immunotherapy
- Childhood Cancer
- Leukemia
- Immunotherapy
- AML
- Lymphoma
- Graft-versus-Host Disease
- Mesenchymal Stem Cells
- Hematopoietic Stem Cells
- Bone Marrow Niche
- Prognostic Factors
- Epidemiology
- Acute Myeloid Leukemia
- Minimal Residual Disease
- Acute Lymphoblastic Leukemia
- Pediatric Oncology
- Infection
- CAR T Cells
- Tumor Regression
- BCR-ABL
- Mutation
- Natural Killer Cells
- Transplantation
- Immunosuppressive Therapy
- Foxp3
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 34 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 34 words, with their numbers
- Hematopoietic Stem Cells8▲ 279×3 topics
- Mesenchymal Stem Cells6▲ 175×2 topics
- Bone Marrow Niche5▲ 713×1 topic
- Graft-versus-Host Disease5▲ 713×1 topic
- Prognostic Factors5▲ 36×5 topics
- Lymphoma3▲ 54×3 topics
- Epidemiology3▲ 2.1×19 topics
- AML2▲ 151×1 topic
- Acute Myeloid Leukemia2▲ 151×1 topic
- Immunotherapy2▲ 10×7 topics
- Minimal Residual Disease2▲ 103×2 topics
- Leukemia2▲ 78×2 topics
- Acute Lymphoblastic Leukemia2▲ 158×1 topic
- Childhood Cancer2▲ 158×1 topic
- Pediatric Oncology2▲ 97×2 topics
- Cancer Immunotherapy2▲ 32×2 topics
- Infection2▲ 21×5 topics
- Rituximab2▲ 32×3 topics
- CAR T Cells1▲ 60×1 topic
- Chimeric Antigen Receptor1▲ 60×1 topic
- Tumor Regression1▲ 41×2 topics
- Inflammation1▲ 1.90×13 topics
- BCR-ABL1▲ 136×1 topic
- Imatinib1▲ 136×1 topic
- Mutation1▲ 20×2 topics
- NK Cell Recognition1▲ 58×1 topic
- Natural Killer Cells1▲ 58×1 topic
- TGF-ß1▲ 25×2 topics
- Transplantation1▲ 39×4 topics
- Autoimmunity1▲ 25×3 topics
- Immunosuppressive Therapy1▲ 18×4 topics
- CD4+CD25+1▲ 95×1 topic
- Foxp31▲ 95×1 topic
- Transplant Recipients1▲ 55×2 topics
Which research topics does The Japanese Data Center for Hematopoietic Cell Transplantation publish most on?
By volume in 2022–2025: Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research and CAR-T cell therapy research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Hematopoietic Stem Cell Transplantation Hematology 5 works
- 2 Acute Myeloid Leukemia Research Hematology 2 works
- 3 Acute Lymphoblastic Leukemia research Public Health, Environmental and Occupational Health 2 works
- 4 CAR-T cell therapy research Oncology 1 works
- 5 Chronic Myeloid Leukemia Treatments Hematology 1 works
- 6 Immune Cell Function and Interaction Immunology 1 works
- 7 T-cell and B-cell Immunology Immunology 1 works
- 8 Renal Transplantation Outcomes and Treatments Transplantation 1 works
- 9 Chronic Lymphocytic Leukemia Research Genetics 1 works
- 10 Cytomegalovirus and herpesvirus research Epidemiology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has The Japanese Data Center for Hematopoietic Cell Transplantation's research output changed?
Output in 2018–2022 was 159% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Nagoya
- Nagoya University
- Nagoya Institute of Technology
- Nagoya City University
- Meijo University
- Aichi Cancer Center
- Toyota Technological Institute
- Aichi Gakuin University
- Nagoya University Hospital
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.